Design and Recruitment for Retinoid Skin Cancer Prevention

Cancer Epidemiology Biomarkers and Prevention

Volumn 4, Issue 6, 1995, Pages 661-669

  Meyskens, Frank ^c   Levine, Norman ^a   Bangert, Jerry ^a   Rodney, Steve ^a   Schreiber, Michael ^a   Peng, Yei Mei ^a   Ritenbaugh, Cheryl ^a   Alberts, David ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN; RETINOID; RETINOL;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN CANCER; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTICARCINOGENIC AGENTS; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; KERATOSIS; MALE; MIDDLE AGED; REGISTRIES; RESEARCH DESIGN; RETINOIDS; SKIN NEOPLASMS;

EID: 0029160550     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Schreiber, M. M., Shapiro, S. I., Berry, C. Z., Dahlen, R. F., Friedman, R. P. The incidence of skin cancer in Southern Arizona. Arch. Dermatol., 104: 124–127, 1971.
2. Schreiber, M. M., Moon, T. E., Meyskens, F. L., and Mudron, J. Solar ultraviolet radiation and skin cancer. Cutis, October, 1982.
3. Scotto, J., and Fraumeni, J. F., Jr. Skin (other than melanoma). In: D. Schottenfeld and J. F. Fraumeni (eds.), Cancer Epidemiology and Prevention, pp. 996–1011. Philadelphia: W. B. Saunders Co., 1982.
4. Epstein, E. Value of follow-up after treatment of basal cell carcinoma. Arch. Dermatol., 108: 798–800, 1973.
5. Freeman, R. G., and Knox, J. M. Recent experience with skin cancer. Arch. Dermatol., 101: 403–408, 1970.
6. Robinson, J. K. Risk of developing another basal cell carcinoma. Cancer (Phila.), 60: 118–120, 1987.
7. Whiting, W. A. Skin tumors in white South Africans. South Afr. Med. J., 53: 162–166, 1978.
8. Zagula-Mally, Z. W., Rosenberg, E. W., and Kashgarian, M. Frequency of skin cancer and solar keratoses in a rural southern county as determined by population sampling. Cancer (Phila.), 34: 349, 1974.
9. Marks, R., Rennie, G., and Selwood, T. S. The relationship of basal cell carcinomas and squamous cell carcinomas to solar keratoses. Arch. Dermatol., 124: 1039–1042, 1988.
10. Greenwald, P., Malone, W. F., Cemy, M. E., and Stem, H. R. Cancer prevention research trials. Adv. Cancer Res., 61: 1–23, 1993.
11. Lippman, S. M., Benner, S. E., and Hong, W. K. Chemoprevention. Strategies for the control of cancer. Cancer (Phila.), 72 (Suppl. 3): 984–990, 1993.
12. Haydey, R. P., Reed, M. L., Dzubow, L. M., and Shupack, J. L. Treatment of keratoacanthomas with oral 13-ri.v-retinoic acid. N. Engl. J. Med., 303: 560–562. 1980.
13. Levine, N., Miller, R. C., and Meyskens, F. L. Oral isotretinoin therapy: use in a patient with multiple cutaneous squamous cell carcinomas and keratoacanthomas. Arch. Dermatol., 120: 1215–1217, 1984.
14. Peck, G. L., DiGiovanna, J. J., Samoff, D. S., Cross, E. G., Butkus, D., Olsen, T. G., and Yoder, F. W. Treatment and prevention of basal cell carcinoma with oral isotretinoin. J. Am. Acad. Dermatol., 19: 176–185, 1988.
15. Shaw, J. C., and White, C. Treatment of multiple keratoacanthomas with oral isotretinoin. J. Am. Acad. Dermatol., 15: 1079–1080, 1986.
16. Hong, W. K., Lippman, S. M., Itri, L. M., Karp, D. D., Lee, J. S., Byers, R. M., Schantz, S. P., Kramer, A. M., Lotan, R., Peters, L. J., Dimery, I. W., Brown, W., and Goepfert, H. Prevention of second primary tumors with isotretinois in squamous-cell carcinoma of the head and neck. N. Engl. J. Med., 323: 795–801, 1990.
17. Hong, W. K., Endicott, J., Itri, L. M., Doos, W., Batsakis, J. G., Bell, R., Fofonoff, S., Byers, R., Atkinson, E. N., Vaughan, C., Toth, B., Kramer, A., Dimery, I. W., Skipper, P., and Strong, S., 13-c7.v-retinoic acid in the treatment of oral leukoplakia. N. Engl. J. Med., 315: 1501–1505, 1986.
18. Meyskens, F. L., Surwit, E., Moon, T. E., Childers, J. M., Davis, J. R., Dorr, R. T., Johnson, C. S., and Alberts, D. S. Enhancement of regression of cervical intra-epithelial neoplasia II (moderate dysplasia) with topically applied all-transretinoic acid: a randomized trial. J. Natl. Cancer Inst., 86: 539–543, 1994.
19. Bollag, W. Vitamin A and retinoids: from nutrition to pharmacotherapy in dermatology and oncology. Lancet, 1: 860–863, 1983.
20. Moon, R. C., Grubbs, C. J., and Spom, M. B. Inhibition of 7,12-dimethyl-benx(«)-anthracene-induced mammary carcinogenesis by retinyl acetate. Cancer Res., 36: 2626–2630. 1976.
21. Saffiotti, U., Montesano, R., Sellarumar, A. R., and Borg, S. A. Experimental cancer of the lung: inhibition by vitamin A of the induction for tracheobronchial squamous metaplasia and squamous cell tumors. Cancer (Phila.), 20: 857–864, 1967.
22. Sporn, M. B., Dunlop, N. M., Newton, D. L., and Smith, J. M. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed. Proc., 35: 1332–1338, 1976.
23. Hill, D. L., and Grubbs, C. J. Retinoids as chemopreventive and anticancer agents in intact animals (Review). Anticancer Res., 2: 111–124, 1982.
24. Goodman, G. E., Metch, B. J., and Omenn, G. S. The effect of long-term β-carotene and vitamin A administration on serum concentrations of α-tocopherol. Cancer Epidemiol., Biomarkers & Prev., 3: 429–432, 1995.
25. Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. U., Mantel, N., McPherson, K., Peto, J., and Smith, P. G. Design and analysis of randomized clinical trials requiring prolonged observations of each patient. I. Introduction and design. Br. J. Cancer, 34: 585–612, 1976.
26. Block, G., Hartman, A. M., Dresser, C. M., Carroll, M. D., Gannon, J., and Gardner, L. A. A data-based approach to diet questionnaire design and testing. Am. J. Epidemiol., 124: 453–469, 1986.
27. National Center of Health Statistics. National Death Index. Hyattsville, MD: Division of Vital Statistics. National Center of Health Statistics, 1988.
28. Korner, W. F., and Vollm, J. New aspects of the tolerance of retinol in humans. Int. J. Vitam. Nutr. Res., 45: 363–372, 1975.
29. Herbert, V. Toxicity of 25,000 IU vitamin A supplements in “health” food users. Am. J. Clin. Nutr., 36: 185–186. 1982.
30. Bershad, S., Rubinstein, A., Patemiti, J. R., Le Ngoc-Anh, Poliak, S. C., Heller, B., Ginsberg, H. N., Gleischmajer, R., and Brown, W. V. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N. Engl. J. Med., 313: 981–985, 1985.
31. Flynn, W. J., Freeman, P. G., and Wickboldt, L. G. Pancreatitis associated with isotretinoin-induced hypertriglyceridemia. Ann. Intern. Med., 107: 63. 1987.
32. Dicken, C. H., and Connolly, S. M. Eruptive xanthomas associated with isotretinoin (13-c7.v-retinoic acid). Arch. Dermatol., 116: 951–952, 1980.
33. Katz, R. A., Jorgensen, H., and Nigra, T. P. Elevation of serum triglyceride levels from oral isotretinoin in disorders of keratinization. Arch. Dermatol., 116: 1369–1372, 1980.
34. Zech, L. A., Gross, E. G., Peck, G. L., and Brewer, H. B. Changes in plasma cholesterol and triglyceride levels after treatment with oral isotretinoin. Arch. Dermatol., 119: 987–993, 1983.
35. Dicken, C. H. Elevation of blood triglyceride levels secondary to administration of vitamin A. Arch. Dermatol., 117: 189–190, 1981.
36. Tangrea, J. A., Adrianza, M. E., Helsel, W. E., Taylor, P. R., Hartman, A. M., Peck, G. L., and Edwards, B. K. Clinical and laboratory adverse effects associated with long-term, low-dose isotretinoin: incidence and risk factors. Cancer Epidemiol., Biomarkers & Prev., 2: 375–380, 1993.
37. Peng, Y. M., Xu, M. J., and Alberts, D. S. Analysis and stability of retinol in plasma. J. Natl. Cancer Inst., 78: 95–98, 1987.
38. Nierenberg, D. W., Peng, Y. M., and Alberts, D. S. Methods for the determination of retinoids, α-tocopherol, and carotenoids in human serum, plasma, and other tissues. In: T. E. Moon and M. Micozzi (eds.). Nutrition and Cancer Prevention: The Role of Micronutrients, pp. 181-209. New York: Marcel Dekker, Inc., 1989.
39. National Institute of Standards and Technology, and National Cancer Institute Micronutrient Measurement Quality Assurance Program, Bethesda, MD, 1994.
40. Greenberg, E. R., Baron, J. A., Stukel, T. A., Stevens, M. M., Mandel, J. S., Spencer, S. K., Elias, P. M., Lowe, N., Neirenberg, D. W., Bayrd, G., Vance, J. C., Freeman, D. H., Clendenennihng, W. E., Kwan, T. and the Skin Cancer Prevention Study Group. A clinical trial of β-carotene to prevent basal-cell and squamous-cell cancers of the skin. N. Engl. J. Med., 323: 789–795, 1990.
41. Lachin, J. M. Introduction to sample size determination and power analyses for clinical trials. Controlled Clin. Trials, 2: 73–113, 1981.
42. Halperin, M., Rogot, E., Gurian, J., and Ederer, F. Sample sizes for medical trials with special reference to long-term therapy. J. Chron. Dis., 21: 13–24, 1968.
43. Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., and Smith, P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br. J. Cancer, 35: 1–39. 1977.
44. Thall, P. F. Mixed Poisson likelihood regression models for longitudinal interval count data. Biometrics, 44: 197–209, 1988.
45. Greenberg, E. R., Baron, J. A., Stevens, M. M., Stuken, T. A., Mandel, J. S., Spencer, S. K., Elias, P. M., Lowe, N., Nierenberg, D. N., Bayrd, G., Vance, J., and the Skin Cancer Prevention Group. The skin cancer prevention study: design of a clinical trial of /3-carotene among persons at high risk for nonmelanoma skin cancer. Controlled Clin. Trials, 10: 153–166, 1989.
46. Tangrea, J., Edwards, B., Hartman, A., Taylor, P., Peck, G., Salasche, S., Menon, P., Winton, G., Mellette, R., Guilll, M., Robinson, J., Guin, J., Stoll, H., and the ISO-BCC Study Group. Isotretinoin-basal cell carcinoma prevention trial. Controlled Clin. Trials, 11: 433–450, 1990.
47. Pastorino, U., Infante, M., Maioli, M., Chiesa, G., Buyse, M., Firket, P., Rosmentz, N., Clerici, M., Soresi, E., Valente, M., Belloni, P. A., and Ravasi, G. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J. Clin. Oncol., 11: 1216–1227, 1993.
48. Tangrea, J. A., Edwards, B. K., Taylor, P. R., Hartman, A. M., Peck, G. L., Salasch, S. J., Menon, P. A., Benson, P. M., Mellette, J. R., Guill, M. A., Robinson, J., Guin, J. D., Stoll, H. L., Gravski, W. J., Winton, G. B., and members of the Isotretinoin Basal Cell Carcinoma Study Group. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. J. Natl. Cancer Inst., 84: 328–332, 1992.